Bristol-Myers Squibb

BMY

Market cap $116B

BMY's FDA filing for mezigdomide in relapsed or refractory multiple myeloma marks another step in advancing its protein degrader pipeline.

Voluntary pricing deals reduce uncertainty for major drugmakers. Drug pricing pressure won't affect every pharmaceutical company equally.

The U.S. Food and Drug Administration (FDA) on Monday accepted the new drug application for Bristol Myers Squibb & Co.'s (NYSE:BMY) investigational oral therapy mezigdomide in combination with carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--U.S. FDA Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma.

Retiring on dividends remains achievable for late starters by building a high-yield, quality portfolio targeting a 6% yield with safe, growing payouts. Dividend-focused strategies mitigate sequence of returns risk, enabling investors to live off income rather than depleting principal during market downturns. Examples like Enbridge Inc. (ENB), Omega Healthcare Investors, Inc. (OHI), and Bristol-Myers Squibb Company (BMY) illustrate our buy low, sell high, and get paid to wait principles, delivering strong returns and dividend growth.

AbbVie is hitting its stride now that it has transitioned past Humira's patent expiration. Medtronic is a steady dividend payer with some intriguing upside in robotics-assisted surgery.

Cancer, type 2 diabetes, and IMIDs continue to spread across the globe, and while pharma stocks are back on Wall Street's radar, they still lag far behind AI-driven names. Also, many of them consistently beat consensus estimates and offer dividend yields that top most oil & gas and IT stocks. In this article, you'll discover my top 5 Big Pharma players.

Bristol Myers Squibb is generating more than enough earnings to cover its dividend right now. However, the company faces a daunting patent cliff.

Bristol Myers Squibb remains a Strong Buy, supported by steady performance and undervaluation despite recent underperformance versus the benchmark. BMY boasts a 4.43% forward dividend yield, over 2.7x the sector median, with 36 years of uninterrupted payments and 18 years of consecutive growth. Recent double-beat earnings and consistent estimate beats since 2024 reinforce positive sentiment and justify a premium valuation.

BMY's growth portfolio now comprises 54.1% of revenues and delivered +9% YoY growth in FQ1'26 against the legacy portfolio's slower erosion, supporting further upside to the currently conservative FY2026 guidance. Strategic partnerships with Jiangsu Hengrui, accretive M&As, and strong uptake of Opdivo Qvantig underpin the company's multi-pronged portfolio renewal efforts, despite the near-term IPRD noise. BMY's intermediate-term top/bottom-line growth prospects are likely to underwhelm due to LOE risks from Eliquis/Opdivo, albeit with secure dividend payouts at 39.2% of free cash flow.